Literature DB >> 27974063

Leishmaniasis and various immunotherapeutic approaches.

Y Taslimi1, F Zahedifard1, S Rafati1.   

Abstract

Leishmaniasis is a vector-borne infectious disease caused by multiple Leishmania (L.) species with diverse clinical manifestations. There is currently no vaccine against any form of the disease approved in humans, and chemotherapy is the sole approach for treatment. Unfortunately, treatment options are limited to a small number of drugs, partly due to high cost and significant adverse effects. The other obstacle in leishmaniasis treatment is the potential for drug resistance, which has been observed in multiple endemic countries. Immunotherapy maybe another important avenue for controlling leishmaniasis and could help patients control the disease. There are different approaches for immunotherapy in different infectious diseases, generally with low-cost, limited side-effects and no possibility to developing resistance. In this paper, different immunotherapy approaches as alternatives to routine drug treatment will be reviewed against leishmaniasis.

Entities:  

Keywords:  cellular therapy; chemoimmunotherapy; chemotherapy; immunotherapy; leishmaniasis; live Leishmania therapy

Mesh:

Substances:

Year:  2016        PMID: 27974063     DOI: 10.1017/S003118201600216X

Source DB:  PubMed          Journal:  Parasitology        ISSN: 0031-1820            Impact factor:   3.234


  16 in total

1.  Aeromonas sobria Induces Proinflammatory Cytokines Production in Mouse Macrophages via Activating NLRP3 Inflammasome Signaling Pathways.

Authors:  Wei Zhang; Zhixing Li; Haitao Yang; Guanglu Wang; Gang Liu; Yu Wang; Babatunde Kazeem Bello; Panpan Zhao; Wei Liang; Jingquan Dong
Journal:  Front Cell Infect Microbiol       Date:  2021-08-26       Impact factor: 5.293

2.  A Community Based Survey of Knowledge, Attitudes, and Practices Concerning Leishmaniasis in Central Morocco.

Authors:  Amane Mounia; Echchakery Mohamed; Hafidi Mohamed; Boussaa Samia
Journal:  J Community Health       Date:  2022-08-03

3.  Comparison of serum cytokine levels in symptomatic and asymptomatic HIV-Leishmania coinfected individuals from a Brazilian visceral leishmaniasis endemic area.

Authors:  Diego Lins Guedes; Elis Dionísio da Silva; Maria Carolina Accioly Brelaz Castro; Walter Lins Barbosa Júnior; Ana Victoria Ibarra-Meneses; Achilleas Tsoumanis; Wim Adriaensen; Johan van Griensven; Valéria Rêgo Alves Pereira; Zulma Maria de Medeiros
Journal:  PLoS Negl Trop Dis       Date:  2022-06-17

4.  Leishmaniasis: current challenges and prospects for elimination with special focus on the South Asian region.

Authors:  Nadira D Karunaweera; Marcelo U Ferreira
Journal:  Parasitology       Date:  2018-04-12       Impact factor: 3.234

5.  Evaluation of in vitro and in vivo Efficacy of a Novel Amphotericin B-Loaded Nanostructured Lipid Carrier in the Treatment of Leishmania braziliensis Infection.

Authors:  Jéssica Rebouças-Silva; Maraine Catarina Tadini; Danielle Devequi-Nunes; Ana Luíza Mansur; Paulo S Silveira-Mattos; Camila I de Oliveira; Fábio R Formiga; Andresa A Berretta; Franciane Marquele-Oliveira; Valéria M Borges
Journal:  Int J Nanomedicine       Date:  2020-11-05

6.  Human Neutrophil Peptide 1 as immunotherapeutic agent against Leishmania infected BALB/c mice.

Authors:  Zahra Abdossamadi; Negar Seyed; Farnaz Zahedifard; Tahereh Taheri; Yasaman Taslimi; Hossein Montakhab-Yeganeh; Alireza Badirzadeh; Mohammad Vasei; Safoora Gharibzadeh; Sima Rafati
Journal:  PLoS Negl Trop Dis       Date:  2017-12-18

7.  Leismanicidal Activity of Propolis Collected in the Semiarid Region of Brazil.

Authors:  Giani Maria Cavalcante; Celso Amorim Camara; Eva Monica Sarmento Da Silva; Mariana Silva Santos; Anderson Brandão Leite; Aline Cavalcanti Queiroz; Amanda Evelyn Da Silva; Morgana Vital Araújo; Magna Suzana Alexandre-Moreira; Tania Maria Sarmento Silva
Journal:  Front Pharmacol       Date:  2021-07-01       Impact factor: 5.810

Review 8.  Immunomodulatory Therapy of Visceral Leishmaniasis in Human Immunodeficiency Virus-Coinfected Patients.

Authors:  Wim Adriaensen; Thomas P C Dorlo; Guido Vanham; Luc Kestens; Paul M Kaye; Johan van Griensven
Journal:  Front Immunol       Date:  2018-01-12       Impact factor: 7.561

Review 9.  New insights into leishmaniasis in the immunosuppressed.

Authors:  Hannah Akuffo; Carlos Costa; Johan van Griensven; Sakib Burza; Javier Moreno; Mercè Herrero
Journal:  PLoS Negl Trop Dis       Date:  2018-05-10

10.  Sirolimus enhances the protection achieved by a DNA vaccine against Leishmania infantum.

Authors:  Alba Martínez-Flórez; Clara Martori; Paula L Monteagudo; Fernando Rodriguez; Jordi Alberola; Alhelí Rodríguez-Cortés
Journal:  Parasit Vectors       Date:  2020-06-09       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.